18.89
price up icon0.85%   0.16
after-market After Hours: 18.89
loading
Tourmaline Bio Inc stock is traded at $18.89, with a volume of 442.07K. It is up +0.85% in the last 24 hours and up +18.66% over the past month. Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.
See More
Previous Close:
$18.73
Open:
$18.64
24h Volume:
442.07K
Relative Volume:
1.25
Market Cap:
$485.28M
Revenue:
-
Net Income/Loss:
$11.77M
P/E Ratio:
32.65
EPS:
0.5785
Net Cash Flow:
$-19.23M
1W Performance:
+14.42%
1M Performance:
+18.66%
6M Performance:
-21.39%
1Y Performance:
+35.80%
1-Day Range:
Value
$18.50
$20.18
1-Week Range:
Value
$15.93
$20.18
52-Week Range:
Value
$11.56
$29.79

Tourmaline Bio Inc Stock (TRML) Company Profile

Name
Name
Tourmaline Bio Inc
Name
Phone
646-481-9832
Name
Address
27 WEST 24TH STREET, NEW YORK
Name
Employee
74
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
TRML's Discussions on Twitter

Compare TRML with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
TRML
Tourmaline Bio Inc
18.89 424.12M 0 11.77M -19.23M 0.5785
Biotechnology icon
ONC
Beone Medicines Ltd Adr
257.00 26.69B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.82 114.81B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.282 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
85.54 6.60B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
483.07 65.36B 14.09B 4.50B 2.96B 39.28

Tourmaline Bio Inc Stock (TRML) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-23-25 Initiated Chardan Capital Markets Buy
Mar-06-25 Initiated Wedbush Outperform
Dec-06-24 Initiated BMO Capital Markets Outperform
Nov-11-24 Reiterated H.C. Wainwright Buy
Dec-15-23 Initiated Jefferies Buy
Dec-04-23 Resumed H.C. Wainwright Buy
Nov-17-23 Initiated Truist Buy
Oct-31-23 Initiated Guggenheim Buy
Oct-25-23 Initiated Piper Sandler Overweight
Oct-20-22 Initiated H.C. Wainwright Buy
Jul-05-22 Downgrade Morgan Stanley Overweight → Equal-Weight
View All

Tourmaline Bio Inc Stock (TRML) Latest News

pulisher
Jun 04, 2025

Nuveen Asset Management LLC Has $1.55 Million Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 04, 2025
pulisher
Jun 03, 2025

BNP Paribas Financial Markets Reduces Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 03, 2025
pulisher
Jun 02, 2025

Jane Street Group LLC Cuts Stock Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 02, 2025
pulisher
Jun 01, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $291,000 Stake in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

Jun 01, 2025
pulisher
May 31, 2025

Deutsche Bank AG Grows Stock Holdings in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

May 31, 2025
pulisher
May 30, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Receives Average Recommendation of “Buy” from Brokerages - Defense World

May 30, 2025
pulisher
May 29, 2025

BMO Sees Overreaction, Maintains Rating and Price Target on Tourmaline Bio (TRML) - MSN

May 29, 2025
pulisher
May 28, 2025

H.C. Wainwright Maintains Buy Rating on Tourmaline Bio (TRML) After Promising Phase 2 Results - Insider Monkey

May 28, 2025
pulisher
May 27, 2025

H.C. Wainwright maintains $50 target on Tourmaline Bio stock By Investing.com - Investing.com India

May 27, 2025
pulisher
May 27, 2025

Millennium Management LLC Has $7.40 Million Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

May 27, 2025
pulisher
May 26, 2025

Leerink Partnrs Comments on Tourmaline Bio FY2026 Earnings - Defense World

May 26, 2025
pulisher
May 25, 2025

Tourmaline Bio Shares Drop After Phase 2 Results for Obesity Drug Pacibekitug Fail to Meet Analyst Expectations - geneonline.com

May 25, 2025
pulisher
May 23, 2025

Tourmaline Bio, Inc. (NASDAQ:TRML) Stock Position Lifted by Northern Trust Corp - Defense World

May 23, 2025
pulisher
May 21, 2025

BMO maintains $35 target on Tourmaline Bio, sees overreaction - Investing.com Australia

May 21, 2025
pulisher
May 21, 2025

Tourmaline Bio stock holds $63 target post-Ph2 data By Investing.com - Investing.com Nigeria

May 21, 2025
pulisher
May 21, 2025

BMO maintains $35 target on Tourmaline Bio, sees overreaction By Investing.com - Investing.com Nigeria

May 21, 2025
pulisher
May 21, 2025

Tourmaline Bio stock holds $63 target post-Ph2 data - Investing.com

May 21, 2025
pulisher
May 21, 2025

Tourmaline shares waver as investors mull mid-stage pacibekitug data - The Pharma Letter

May 21, 2025
pulisher
May 21, 2025

In Brief: Tourmaline Reports Positive Topline Phase II Results for Pacibekitug In CKD - insights.citeline.com

May 21, 2025
pulisher
May 21, 2025

Tourmaline Bio (TRML) Shares Drop After Trial Data Release - GuruFocus

May 21, 2025
pulisher
May 20, 2025

Tourmaline Bio: TRANQUILITY Study Data Lends Credibility For IL-6 Inhibition - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

Gold Gains Over 1%; Amer Sports Posts Upbeat Earnings - Benzinga

May 20, 2025
pulisher
May 20, 2025

Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff - BioPharma Dive

May 20, 2025
pulisher
May 20, 2025

Buy Rating for Tourmaline Bio Driven by Promising Clinical Results and Market Potential - TipRanks

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets - Endpoints News

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Says Pacibekitug Trial Showed 'Deep, Durable Reduction' in High-Sensitivity C-Reactive Protein - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Transcript : Tourmaline Bio, Inc.Special Call - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Announces Positive Phase 2 Trial Results - TipRanks

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Reports Positive Topline Data From Phase 2 TRANQUILITY Study - Nasdaq

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio stock slips after trial data (TRML:NASDAQ) - Seeking Alpha

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Announces Positive Topline Results from the Ongoing Phase 2 TRANQUILITY Trial - marketscreener.com

May 20, 2025
pulisher
May 20, 2025

Tourmaline shares edge lower despite phase 2 trial results - Investing.com Australia

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio (TRML) Reports Encouraging Results from Phase 2 C - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Tourmaline Bio Announces Positive Topline Results from the - GlobeNewswire

May 20, 2025
pulisher
May 20, 2025

Breakthrough Clinical Trial: New Quarterly Drug Cuts Heart Disease Risk Marker by 85% in Kidney Disease Patients - Stock Titan

May 20, 2025
pulisher
May 19, 2025

Tourmaline Bio to reveal Phase 2 trial results tomorrow By Investing.com - Investing.com South Africa

May 19, 2025
pulisher
May 19, 2025

Tourmaline Bio to reveal Phase 2 trial results tomorrow - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Tourmaline Bio to Host Conference Call on Phase 2 TRANQUILITY Trial Results for Pacibekitug in Chronic Kidney Disease - Nasdaq

May 19, 2025
pulisher
May 19, 2025

Major Phase 2 Trial Results Coming: Tourmaline Bio's Novel CKD Drug Could Transform Patient Care - Stock Titan

May 19, 2025
pulisher
May 16, 2025

Tower Research Capital LLC TRC Increases Position in Tourmaline Bio, Inc. (NASDAQ:TRML) - Defense World

May 16, 2025
pulisher
May 14, 2025

Contrasting Fennec Pharmaceuticals (NASDAQ:FENC) and VectivBio (NASDAQ:VECT) - Defense World

May 14, 2025
pulisher
May 12, 2025

Tourmaline Bio’s Pacibekitug: A Promising IL-6 Inhibitor for ASCVD with Strong Buy Rating - TipRanks

May 12, 2025
pulisher
May 10, 2025

Raymond James Financial Inc. Takes Position in Commercial Vehicle Group, Inc. (NASDAQ:CVGI) - Defense World

May 10, 2025
pulisher
May 10, 2025

Barclays PLC Increases Position in Chicago Atlantic Real Estate Finance, Inc. (NASDAQ:REFI) - Defense World

May 10, 2025
pulisher
May 10, 2025

Barclays PLC Acquires 5,175 Shares of Tile Shop Holdings, Inc. (NASDAQ:TTSH) - Defense World

May 10, 2025
pulisher
May 10, 2025

Barclays PLC Purchases Shares of 24,107 Grail, Inc. (NASDAQ:GRAL) - Defense World

May 10, 2025
pulisher
May 10, 2025

Barclays PLC Acquires 42,792 Shares of MicroVision, Inc. (NASDAQ:MVIS) - Defense World

May 10, 2025
pulisher
May 10, 2025

Tourmaline Bio (TRML) to Release Quarterly Earnings on Monday - Defense World

May 10, 2025
pulisher
May 09, 2025

FY2025 EPS Estimates for Tourmaline Bio Decreased by Analyst - Defense World

May 09, 2025
pulisher
May 09, 2025

Chardan Capital Raises Earnings Estimates for Tourmaline Bio - Defense World

May 09, 2025

Tourmaline Bio Inc Stock (TRML) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Tourmaline Bio Inc Stock (TRML) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Kulkarni Sandeep Chidambar
CEO
Aug 16 '24
Buy
13.79
5,221
71,998
5,221
$1.15
price down icon 0.86%
$580.59
price up icon 1.24%
$308.00
price up icon 0.88%
$36.54
price up icon 1.27%
$4.8111
price up icon 1.29%
$483.07
price down icon 0.38%
Cap:     |  Volume (24h):